Results 51 to 60 of about 6,081 (225)

Effect of levosimendan on prognosis in adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials

Critical Care, 2017
Background Small trials suggest that levosimendan is associated with a favorable outcome in patients undergoing cardiac surgery. However, recently published larger-scale trials did not provide evidence for a similar benefit from levosimendan.
Qi-Hong Chen, Rui-Qiang Zheng, Hua Lin, Jun Shao, Jiang-quan Yu, Hua-Ling Wang   +5 more
doaj   +1 more source

Effect of levosimendan infusion prior to left ventricular assist device implantation on right ventricular failure

Journal of Cardiothoracic Surgery, 2022
Objective Investigate the safety and efficacy of preoperative levosimendan in patients undergoing left ventricular assist device (LVAD) implantation.
Amitai Segev, Jacob Lavee, Yigal Kassif, Yedida Shemesh, Alexander Kogan, Dov Freimark, Avi Morgan, Dor Lotan, Edward Itelman, Avishay Grupper   +9 more
doaj   +1 more source

Initial clinical experience with dapagliflozin in addition to optimized medical therapy in paediatric heart failure patients

ESC Heart Failure, Volume 12, Issue 5, Page 3494-3501, October 2025.
Abstract Aims Dapagliflozin, a sodium‐glucose cotransporter 2 (SGLT2) inhibitor, has shown clinical benefits in adults with heart failure (HF), improving cardiac function, reducing HF‐related hospitalizations and enhancing survival rates. While extensively studied in adult HF, data on its efficacy and safety in paediatric HF patients remain limited. We
Lisa‐Maria Rosenthal, Oliver Miera, Annemarie Krauss, Friederike Danne, Felix Berger, Peter Kramer   +5 more
wiley   +1 more source

Pro‐ and Anti‐Inflammatory Responses and Clinical Outcomes in Critically Ill Patients With Endotheliopathy: A Cohort Study

Acta Anaesthesiologica Scandinavica, Volume 69, Issue 9, October 2025.
ABSTRACT Background Multiple organ dysfunction syndrome (MODS) in critical illness involves dysregulated immune and inflammatory responses, endotheliopathy, and coagulation activation. We investigated how three types of endotheliopathy biomarkers relate to pro‐ and anti‐inflammatory responses and clinical outcomes in intensive care unit (ICU) patients.
Caroline Humble, Martin Schønemann‐Lund, Peter Bruun‐Rasmussen, Morten H. Bestle, Pär I. Johansson, Lone M. Poulsen, Ole Mathiesen   +6 more
wiley   +1 more source

İleri kalp yetersizliği hastalarında levosimendanın eritrosit dağılım genişliği üzerine etkisi

Genel Tıp Dergisi, 2015
Amaç: Levosimendan dekompanse kalp yetersizliğinde kullanılan, olumlu hemodinamik etkileri de olan pozitif inotropik bir ilaçtır. Bu çalışmanın amacı levosimendan tedavisi almış ileri kalp yetersizliği hastalarının tedavi öncesi ve sonrası eritrosit ...
Ahmet Gürel, Niyazi Güler, Murat Aydın, Şeref Alpsoy, Aydın Akyüz, Dursun Çayan Akkoyun   +5 more
doaj  

Impact of levosimendan on weaning from peripheral venoarterial extracorporeal membrane oxygenation in intensive care unit

Annals of Intensive Care, 2019
Background Few data are available on the impact of levosimendan in refractory cardiogenic shock patients undergoing peripheral venoarterial extracorporeal membrane oxygenation (VA-ECMO). The aim of this study was to evaluate the impact of levosimendan on
Shamir Vally, Cyril Ferdynus, Romain Persichini, Bruno Bouchet, Eric Braunberger, Hugo Lo Pinto, Olivier Martinet, David Vandroux, Thomas Aujoulat, Jérôme Allyn, Nicolas Allou   +10 more
doaj   +1 more source

Simultaneous LC-ESI-MS/MS Quantification of Levosimendan and Its Metabolites for Therapeutic Drug Monitoring of Cardiac Surgery Patients

Pharmaceutics, 2022
Levosimendan is used in severe chronic cardiac insufficiency, also within the peri-operative setting. Real-life pharmacokinetic data in surgical patients is lacking, making therapeutic drug monitoring (TDM) of levosimendan, its pharmacologically active ...
Hannah Kipka, Roland Tomasi, Max Hübner, Uwe Liebchen, Christian Hagl, Klaus T. Wanner, Hanna Mannell, Georg Höfner   +7 more
doaj   +1 more source

Levosimendan as a new force in the treatment of sepsis-induced cardiomyopathy: mechanism and clinical application

Journal of International Medical Research, 2019
The heart is one of the organs most vulnerable to sepsis. This review describes the general characteristics of sepsis-induced cardiomyopathy and the main pathogenesis of myocardial dysfunction in sepsis.
Fei Yang, Li Na Zhao, Yi Sun, Zhuang Chen   +3 more
doaj   +1 more source

Effect of levosimendan, a calcium sensitizer, on cisplatin-induced nephrotoxicity in rats

Toxicology Reports, 2019
We investigated the effect of levosimendan on cisplatin (Cis)-induced nephrotoxicity. Rats were divided into four groups (n = 6). The first and second groups received normal saline (control) and intraperitoneal (i.p.) cisplatin (6 mg/kg) on day 7 ...
Aly M. Abdelrahman, Yousuf Al Suleimani, Asem Shalaby, Mohammed Ashique, Priyadarsini Manoj, Hasna Al-Saadi, Badreldin H. Ali   +6 more
doaj   +1 more source

Levosimendan versus dobutamine for sepsis-induced cardiac dysfunction: a systematic review and meta-analysis

Scientific Reports, 2021
Levosimendan and dobutamine are extensively used to treat sepsis-associated cardiovascular failure in ICU. Nevertheless, the role and mechanism of levosimendan in patients with sepsis-induced cardiomyopathy remains unclear.
Dong-Hua Liu, Yi-Le Ning, Yan-Yan Lei, Jing Chen, Yan-Yan Liu, Xin-Feng Lin, Zhong-Qi Yang, Shao-Xiang Xian, Wei-Tao Chen   +8 more
doaj   +1 more source